Abstract
Combined therapy by simvastatin and ezetimibe and its cardioprotective effects assessed in IMPROVE-IT Study brings broad use in every day clinical practice, especially in patients with high and very high cardiovascular risk, who do not tolerate high dose of statins and /or high effective statins.The combination of mentioned lipid modifying drugs is very well tolerated and that is why compliance to that therapy could be improve in high risk patients. Pleiotropic effects of ezetimibe on insulin resistance and atherogenic dyslipidemia could not be forgotten, because it could be an important effect, how to reduce residual vascular risk.